141 related articles for article (PubMed ID: 7733405)
21. Opioids and differentiation in human cancer cells.
Zagon IS; McLaughlin PJ
Neuropeptides; 2005 Oct; 39(5):495-505. PubMed ID: 16169076
[TBL] [Abstract][Full Text] [Related]
22. An opioid growth factor regulates the replication of microorganisms.
Zagon IS; McLaughlin PJ
Life Sci; 1992; 50(16):1179-87. PubMed ID: 1313136
[TBL] [Abstract][Full Text] [Related]
23. Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy.
Wang R; Zhang Y; Shan F
Int Immunopharmacol; 2019 Oct; 75():105785. PubMed ID: 31404891
[TBL] [Abstract][Full Text] [Related]
24. The autocrine derivation of the opioid growth factor, [Met5]-enkephalin, in ocular surface epithelium.
Zagon IS; Sassani JW; Wu Y; McLaughlin PJ
Brain Res; 1998 May; 792(1):72-8. PubMed ID: 9593829
[TBL] [Abstract][Full Text] [Related]
25. Human renal cell cancer proliferation in tissue culture is tonically inhibited by opioid growth factor.
Bisignani GJ; McLaughlin PJ; Ordille SD; Beltz MS; Jarowenko MV; Zagon IS
J Urol; 1999 Dec; 162(6):2186-91. PubMed ID: 10569617
[TBL] [Abstract][Full Text] [Related]
26. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.
McLaughlin PJ; Zagon IS
Biochem Pharmacol; 2012 Sep; 84(6):746-55. PubMed ID: 22687282
[TBL] [Abstract][Full Text] [Related]
27. The Yin and Yang of the Opioid Growth Regulatory System: Focus on Diabetes-The Lorenz E. Zimmerman Tribute Lecture.
Sassani JW; Mc Laughlin PJ; Zagon IS
J Diabetes Res; 2016; 2016():9703729. PubMed ID: 27703986
[TBL] [Abstract][Full Text] [Related]
28. Nucleocytoplasmic distribution of opioid growth factor and its receptor in tongue epithelium.
Zagon IS; Ruth TB; McLaughlin PJ
Anat Rec A Discov Mol Cell Evol Biol; 2005 Jan; 282(1):24-37. PubMed ID: 15584033
[TBL] [Abstract][Full Text] [Related]
29. Opioid growth factor ([Met5]enkephalin) prevents the incidence and retards the growth of human colon cancer.
Zagon IS; Hytrek SD; Lang CM; Smith JP; McGarrity TJ; Wu Y; McLaughlin PJ
Am J Physiol; 1996 Sep; 271(3 Pt 2):R780-6. PubMed ID: 8853403
[TBL] [Abstract][Full Text] [Related]
30. Naltrexone, an opioid antagonist, facilitates reepithelialization of the cornea in diabetic rat.
Zagon IS; Jenkins JB; Sassani JW; Wylie JD; Ruth TB; Fry JL; Lang CM; McLaughlin PJ
Diabetes; 2002 Oct; 51(10):3055-62. PubMed ID: 12351447
[TBL] [Abstract][Full Text] [Related]
31. Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.
McLaughlin PJ; Zagon IS; Park SS; Conway A; Donahue RN; Goldenberg D
BMC Cancer; 2009 Oct; 9():369. PubMed ID: 19835629
[TBL] [Abstract][Full Text] [Related]
32. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.
Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
Immunobiology; 2011; 216(1-2):173-83. PubMed ID: 20598772
[TBL] [Abstract][Full Text] [Related]
33. Blockade of OGFr delays the onset and reduces the severity of diabetic ocular surface complications.
Zagon IS; Sassani JW; Purushothaman I; McLaughlin PJ
Exp Biol Med (Maywood); 2021 Mar; 246(5):629-636. PubMed ID: 33203224
[TBL] [Abstract][Full Text] [Related]
34. Opioid growth factor (OGF) inhibits human pancreatic cancer transplanted into nude mice.
Zagon IS; Hytrek SD; Smith JP; McLaughlin PJ
Cancer Lett; 1997 Jan; 112(2):167-75. PubMed ID: 9066724
[TBL] [Abstract][Full Text] [Related]
35. Selective blockade of the OGF-OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing.
Immonen JA; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2014 Oct; 239(10):1300-9. PubMed ID: 25030485
[TBL] [Abstract][Full Text] [Related]
36. Expression of the opioid growth factor, [Met5]-enkephalin, and the zeta opioid receptor in head and neck squamous cell carcinoma.
Levin RJ; Wu Y; McLaughlin PJ; Zagon IS
Laryngoscope; 1997 Mar; 107(3):335-9. PubMed ID: 9121309
[TBL] [Abstract][Full Text] [Related]
37. Regulation of human head and neck squamous cell carcinoma growth in tissue culture by opioid growth factor.
McLaughlin PJ; Levin RJ; Zagon IS
Int J Oncol; 1999 May; 14(5):991-8. PubMed ID: 10200353
[TBL] [Abstract][Full Text] [Related]
38. Endogenous opioid systems regulate cell proliferation in the developing rat brain.
Zagon IS; McLaughlin PJ
Brain Res; 1987 May; 412(1):68-72. PubMed ID: 3607463
[TBL] [Abstract][Full Text] [Related]
39. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
Donahue RN; McLaughlin PJ; Zagon IS
Gynecol Oncol; 2011 Aug; 122(2):382-8. PubMed ID: 21531450
[TBL] [Abstract][Full Text] [Related]
40. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model.
Donahue RN; McLaughlin PJ; Zagon IS
Exp Biol Med (Maywood); 2011 Sep; 236(9):1036-50. PubMed ID: 21807817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
